Sensei Biotherapeutics (SNSE) 25th Annual Needham Virtual Healthcare Conference summary

Strategic updates and financial highlights

• Completed a reverse merger with Sensei Biotherapeutics and raised $200 million in a private placement to fund lead programs, merging leadership teams and focusing capital on advancing the PIKTOR program, with key data readouts expected by year-end 2026.

• Emphasizing multi-node inhibition in cancer metabolism, targeting the PI3K/AKT/mTOR pathway with two oral small molecules, aiming for improved efficacy and tolerability over single-node or intravenous therapies.

• Recent phase II and Ib studies in endometrial, ovarian, and breast cancers showed promising efficacy and safety, with notable response rates and favorable tolerability, especially in heavily pretreated populations.

• Pipeline prioritizes PIKTOR, with additional programs in development and a robust patent portfolio extending into the late 2030s and potentially 2040s.

• Upcoming catalysts include endometrial cancer data in late 2026 and breast cancer safety and efficacy data through 2027.

Clinical development and scientific insights

• Multi-node inhibition with serabelisib (PI3K-alpha inhibitor) and sapanisertib (TORC1/2 inhibitor) achieves more complete pathway shutdown, reducing resistance and expanding the addressable patient population.

• Oral administration and unique dosing regimens provide pharmacokinetic advantages, maintaining drug exposure above efficacy thresholds and minimizing adverse events like stomatitis and hyperglycemia.

• Phase Ib data showed a 47% overall response rate in advanced solid tumors, with activity across various mutational subtypes and favorable safety, even in medication-dependent diabetics.

• Endometrial cancer trials target a population with high unmet need, aiming for significant efficacy improvements over current second-line therapies.

• Positive randomized phase II results in platinum-resistant ovarian cancer and plans to expand combination studies with additional agents.

Competitive landscape and regulatory positioning

• Differentiation from next-gen selective PI3K inhibitors is based on broader efficacy, lower hyperglycemia rates, and convenience of oral dosing, with no current market alternatives matching the unique target profile.

• Safety and efficacy data in endometrial cancer are expected to de-risk future breast cancer studies, given the challenging metabolic profile of endometrial patients.

• Regulatory strategy leverages a large inherited safety database and ongoing FDA engagement, with ample drug supply and CMC readiness for upcoming trials.

• Oral regimens are positioned as increasingly important in breast cancer, aiming to improve patient quality of life and meet evolving standards of care.

• Future studies will benchmark against competitors and explore novel combinations to address evolving treatment paradigms.